DocMorris AGXSWX:DOCM +4.22%65 EV-to-EBITDA is -9.07 as of Jul. 02, 2026. GuruFocus rates XSWX:DOCM with a GF Score™ of 65/100 and a GF Value™ of CHF10.55 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 507 Healthcare Providers & Services companies, DocMorris AG ranks worse than 197238.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DocMorris AG's enterprise value is CHF528 Mil.
DocMorris AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-58 Mil. Therefore, DocMorris AG's EV-to-EBITDA for today is -9.07.
The historical rank and industry rank for DocMorris AG's EV-to-EBITDA or its related term are showing as below:
XSWX:DOCM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -663.97 Med: -22.4 Max: -3.08
Current: -9.06
During the past 13 years, the highest EV-to-EBITDA of DocMorris AG was -3.08. The lowest was -663.97. And the median was -22.40.
XSWX:DOCM's EV-to-EBITDA is ranked worse than 100% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.87
vs XSWX:DOCM: -9.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
DocMorris AG (XSWX:DOCM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DocMorris AG's PE Ratio (TTM) for today is calculated as:
DocMorris AG's share price for today is CHF9.13.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DocMorris AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-4.582.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for DocMorris AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, DocMorris AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocMorris AG EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DocMorris AG's EV-to-EBITDA falls into.
DocMorris AG's current Enterprise Value is CHF528 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DocMorris AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DocMorris AG (XSWX:DOCM) has a EV-to-EBITDA of -9.07 as of Jul. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DocMorris AG. According to the industry distribution chart, DocMorris AG ranks #999999 out of 507 companies in the Healthcare Providers & Services industry.
Is DocMorris AG's EV-to-EBITDA too high?
DocMorris AG's current EV-to-EBITDA is -9.07. Based on the distribution chart, DocMorris AG ranks #999999 out of 507 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #999999 out of 507 companies for EV-to-EBITDA. This places DocMorris AG in the lower half of its industry. The industry median EV-to-EBITDA is 10.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.87, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DocMorris AG. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current EV-to-EBITDA is -9.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.55, compared to a current price of CHF9.13 — trading 13.5% below its estimated fair value. The current EV-to-EBITDA is -9.07. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current EV-to-EBITDA is -9.07 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF9.13 is trading 13.5% below its estimated GF Value™ of CHF10.55.
GuruFocus considers DocMorris AG to be Modestly Undervalued.
Key valuation signals for XSWX:DOCM:
EV-to-EBITDA: -9.07
GF Value™: CHF10.55 vs. price of CHF9.13 (13.5% below fair value)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score
Get the complete analysis for XSWX:DOCM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 
